Journals Human Vaccines & Immunotherape...

Human Vaccines & Immunotherapeutics
Sergei S Biryukov, Nathaniel O Rill, Christopher P Klimko, Jennifer L Dankmeyer, Jennifer L Shoe, Melissa Hunter, Yuli Talyansky, Derrick Hau, Marcellene A Gates-Hollingsworth, Sujata G Pandit, David P Fetterer, Ju Qiu, Michael L Davies, David P AuCoin, Christopher K Cote
Yersinia pestis is a gram-negative bacterium that causes plague in animals and humans. Depending on the route of disease transmission, the bacterium can cause an acute, often fatal disease that has a narrow window for treatment with antibiotics. Additionally, antibiotic resistant strains have been identified, emphasizing the need for novel treatments. Antibody therapy is an appealing option that can direct the immune system to clear bacterial infections. Advances in biotechnology have made both engineering and producing antibodies easier and more affordable...
June 8, 2023: Human Vaccines & Immunotherapeutics
Ke Xu, Bingqian Gao, Jiayi Li, Yixin Xiang, Lin Cao, Mingyi Zhao
Vogt-Koyanagi-Harada (VKH) disease is a rare and serious ocular adverse reaction following COVID-19 vaccination. This study aimed to evaluate the clinical features, diagnosis and management of COVID-19 vaccine-associated VKH disease. Case reports of VKH disease after COVID-19 vaccination were collected up to February 11, 2023 for retrospective analysis. Twenty-one patients (9 males and 12 females) were included, with a median age of 45 years (range 19-78), from three main regions, Asia (12/21), the Mediterranean region (4/21), and South America (5/21)...
June 6, 2023: Human Vaccines & Immunotherapeutics
Kathryn Kline, Wengen Chen, Michael E Kallen, Rima Koka, Destiny Omili, Xiaoxuan Fan, Thierry Iraguha, Etse Gebru, Nishanthini Dishanthan, Jillian M Baker, Kenneth A Dietze, Jean A Yared, Kim Hankey, Saurabh Dahiya, Silke V Niederhaus, Kieron Dunleavy, Nancy M Hardy, Tim Luetkens, Aaron P Rapoport, Djordje Atanackovic
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication following kidney transplantation, and there is a critical and unmet need for PTLD treatments associated with more pronounced and durable responses. To date, reports on the use of CD19-targeted chimeric antigen receptor (CAR) T (CAR-T) cells in patients after solid organ transplant (SOT) have been anecdotal, clinical presentations and outcomes have been heterogenous, and a longitudinal analysis of CAR-T cell expansion and persistence in PTLD patients has not been reported...
June 6, 2023: Human Vaccines & Immunotherapeutics
Patrick Dmc Katoto, Jacques L Tamuzi, Amanda S Brand, Diana M Marangu, Liliane N Byamungu, Charles S Wiysonge, Glenda Gray
The rapid emergence of COVID-19 variants of concern (VOCs) has hindered vaccine uptake. To inform policy, we investigated the effectiveness of the BNT162b2 vaccination among adolescents against symptomatic and severe COVID-19 diseases using mostly real-world data (15 studies). We searched international databases until May 2022 and used Cochrane's risk of bias tools for critical appraisal. Random effects models were used to examine overall vaccine effectiveness (VE) across studies (general inverse-variance) and the effect of circulating VOCs on VE (log relative ratio and VE)...
June 5, 2023: Human Vaccines & Immunotherapeutics
Amnuay Kleebayoon, Viroj Wiwanitkit
No abstract text is available yet for this article.
June 4, 2023: Human Vaccines & Immunotherapeutics
Thomas E Hickey, Troy J Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R Lowy, Ligia A Pinto
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor recipients of either vaccine (BNT162b2 n  = 53, mRNA-1273 n  = 49; age 23-67), and individuals naturally infected with SARS-CoV-2 ( n  = 106; age 18-82) were collected 0-2 months post-infection or 1- and 4 months after second dose of vaccination...
June 1, 2023: Human Vaccines & Immunotherapeutics
Xiaoyuan Huang, Jing Liang, Lili Huang, Xuanxuan Nian, Wei Chen, Jiayou Zhang, Xiao Xu, Xuan Lin, Yue Wang, Jinrong Shi, Lanxin Jia, Qingliang Li, Qianxi Wang, Kai Duan, Xinguo Li, Yaqi Ji, Feixia Peng, Wei Zhang, Zhiqiang Xie, Yanxia Wang, Xiaoming Yang
This phase III clinical trial aimed to assess the safety and demonstrate the immunogenicity of a candidate freeze-dried purified Vero cell-based rabies vaccine (PVRV-WIBP) developed for human use. A cohort of 40 participants in stage 1 and 1956 subjects in stage 2 with an age range of 10-50 years were recruited for the phase III clinical trial. For safety analysis in stage 1, 20 participants received either 4-dose or 5-dose regimen of PVRV-WIBP. In stage 2, 1956 subjects were randomly divided into the 5-dose PVRV-WIBP, 5-dose PVRV-LNCD, and 4-dose PVRV-WIBP groups...
May 30, 2023: Human Vaccines & Immunotherapeutics
Eszter Török, Tavleen Dhinsa, Sheryll Dimanlig-Cruz, Gillian D Alton, Ann E Sprague, Sandra I Dunn, Prakesh S Shah, Darine El-Chaâr, Annette K Regan, Kumanan Wilson, Sarah A Buchan, Jeffrey C Kwong, Siri E Håberg, Christopher A Gravel, Nannette Okun, Mark C Walker, Shannon E MacDonald, Sarah E Wilson, Jon Barrett, Deshayne B Fell
During the rapid deployment of COVID-19 vaccines in 2021, safety concerns may have led some pregnant individuals to postpone vaccination until after giving birth. This study aimed to describe temporal patterns and factors associated with COVID-19 vaccine series initiation after recent pregnancy in Ontario, Canada. Using the provincial birth registry linked with the COVID-19 vaccine database, we identified all individuals who gave birth between January 1 and December 31, 2021, and had not yet been vaccinated by the end of pregnancy, and followed them to June 30, 2022 (follow-up ranged from 6 to 18 months)...
May 30, 2023: Human Vaccines & Immunotherapeutics
Li-Wei Shi, Juan Li, Bang-Wei Yu, Li-Rong Huang, Ke Li, Min Ji, Ling-Yun Zhou, Lin Yuan, Shu-Yuan Yang, Jing-Jing Chen, Ling Wang, Zhi-Wei Jiang, Rong-Cheng Li, Yan-Ping Li, Jie-Lai Xia, Zhao-Jun Mo, Chang-Gui Li
As global supply is still inadequate to address the worldwide requirements for HPV vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine. In this randomized, double-blind, placebo-controlled, phase 2 trial, healthy 9-45-year-old Chinese females in three age cohorts (600 aged 9-17 years; 240 aged 18-26 years; 360 aged 27-45 years) were randomized 1:1 to receive three doses (0,2,6 months) of HPV16/18 vaccine or placebo. We measured neutralizing antibodies against HPV 16 and 18 at 7 months and monitored safety to 12 months in all age cohorts; 9-17-year-old girls were monitored for safety and immunogenicity to 48 months...
May 30, 2023: Human Vaccines & Immunotherapeutics
Noel T Brewer, Benjamin Z Kahn, Katherine I Kritikos, Jennifer A Heisler-MacKinnon, Jessica D Young, Melissa B Gilkey
This article provides best and promising practices for recommending HPV vaccination at age 9 as a way to ensure high uptake. An effective method for recommending HPV vaccination is the Announcement Approach, which consists of 3 evidence-based steps. The first step, Announce , involves noting that the child is 9 years old, saying they are due for a vaccine that prevents 6 HPV cancers, and saying you'll vaccinate today. This adapted version of the Announce step simplifies the bundled approach used at ages 11-12 that emphasizes the prevention of meningitis and whooping cough in addition to HPV cancers...
May 29, 2023: Human Vaccines & Immunotherapeutics
Yongmei Ma, Xiyan Xia, Wen Zheng, Yonggang Dai, Xuewei Zhuang
Since March 2020, the pandemic caused by SARS-CoV-2 has affected nearly all aspects of daily life. In this study, we investigated the age-stratified prevalence and genotype distribution of human papillomavirus (HPV) among females in Shandong province (eastern China) and aimed to provide guidance on HPV-based cervical cancer screening and vaccination. The distribution of HPV genotypes was analyzed using PCR-Reverse Dot Hybridization. The overall infection rate of HPV was 16.4%, which was dominated by high-risk genotypes...
May 25, 2023: Human Vaccines & Immunotherapeutics
Francesca Fortunato, Rosa Prato, Giuseppina Iannelli, Leonardo Ascatigno, Daniela Loconsole, Pier Luigi Lopalco, Domenico Martinelli
During COVID-19 vaccination campaign, possible ChAdOx1-S-associated risks of thrombosis with thrombocytopenia syndrome led to implement ChAdOx1-S/BNT162b2 heterologous vaccination, despite the limited information on its reactogenicity and safety. We conducted a prospective observational post-marketing surveillance study to assess the safety of this heterologous schedule. A casually selected sample of recipients (n: 85; age: 18-60 years) of ChAdOx1-S/BNT162b2 at the vaccination hub of the Foggia Hospital, Italy, was matched with an equal sample of recipients of homologous BNT162b2...
May 25, 2023: Human Vaccines & Immunotherapeutics
Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriquez, Camilo A Rodriguez, Josefina Carlos, May Emmeline B Montellano, Edison R Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
We previously demonstrated the efficacy of the COVID-19 vaccine candidate, SCB-2019, in adults in the SPECTRA phase 2/3 efficacy study. We extended the study to include 1278 healthy 12-17-year-old adolescents in Belgium, Colombia, and the Philippines who received either two doses of SCB-2019 or placebo 21 days apart, to assess immunogenicity as neutralizing antibodies against prototype SARS-CoV-2 and variants of concern, and safety and reactogenicity as solicited and unsolicited adverse events with a comparator group of young adults (18-25 years)...
May 25, 2023: Human Vaccines & Immunotherapeutics
Ji-Young Hwang, Yunhwa Kim, Kyung-Min Lee, Ok Sarah Shin, Jeong-An Gim, Younchul Shin, Hosun Park
The currently used Japanese Oka and Korean MAV/06-attenuated varicella vaccine strains belong to clade 2 genotype varicella-zoster viruses (VZV). More than seven clades of VZV exist worldwide. In this study, we investigated the cross-reactivity of antibodies induced by clade 2 genotype vaccines against VZV strains belonging to clades 1, 2, 3, and 5 using a fluorescent antibody to membrane antigen (FAMA) test. Among 59 donors, 29 were vaccinated with the MAV/06 strain MG1111 (GC Biopharma, South Korea) and the other 30 were vaccinated with the Oka strain VARIVAX (Merck, USA)...
May 23, 2023: Human Vaccines & Immunotherapeutics
Robert A Bednarczyk, Noel T Brewer, Melissa B Gilkey, Sherri Zorn, Rebecca B Perkins, Kristin Oliver, Debbie Saslow
The Advisory Committee on Immunization Practices (ACIP) has recommended human papillomavirus (HPV) vaccination for adolescents in the United States since 2006. Though recommended at a similar time to the routine recommendations for adolescent tetanus, diphtheria, and acellular pertussis vaccination (Tdap) and quadrivalent meningococcal vaccination (MCV4), HPV vaccine uptake has consistently lagged behind these other adolescent vaccines. The ACIP recommends HPV vaccination at 11-12 y, with vaccination starting at 9 y of age included as an option that is routinely encouraged by the American Academy of Pediatrics and American Cancer Society...
May 23, 2023: Human Vaccines & Immunotherapeutics
Po-Ching Huang, I-Hua Chen, Luca Barlassina, James R Turner, Felipe Carvalho, Alvaro Martinez-Perez, Jilly Gibson-Miller, Miklós Kürthy, Kuo-Hsin Lee, Mark D Griffiths, Chung-Ying Lin
Vaccination can sufficiently ameliorate the coronavirus disease-2019 (COVID-19). Investigating what factors influence vaccine uptake may benefit ongoing vaccination efforts (e.g. booster injections, annual vaccination). The present study expanded Protection Motivation Theory with possible factors including perceived knowledge, adaptive responses, and maladaptive responses to develop a proposed model investigating vaccine uptake among United Kingdom (UK) and Taiwan (TW) populations. An online survey collected responses from UK ( n  = 751) and TW ( n  = 1052) participants (August to September, 2022)...
May 22, 2023: Human Vaccines & Immunotherapeutics
Ashley Hedrick McKenzie, Ross Shegog, Lara S Savas, C Mary Healy, L Aubree Shay, Sharice Preston, Sharon Coan, Travis Teague, Erica Frost, Stanley W Spinner, Sally W Vernon
Parents' stigmatizing beliefs about the HPV vaccine, such as beliefs that it promotes adolescent sexual activity, constitute a notable barrier to vaccine uptake. The purpose of this study is to describe the associations between parents' stigmatizing beliefs about the HPV vaccine, psychosocial antecedents to vaccination, and parents' intentions to vaccinate their children. Parents of vaccine-eligible children ( n  = 512) were surveyed in a large urban clinical network. Results indicate that two stigmatizing beliefs were significantly associated with self-efficacy in talking with a doctor about the HPV vaccine...
May 22, 2023: Human Vaccines & Immunotherapeutics
Xiwen Luo, Jing Tao, Min Pang, Zhiyong Zhang, Xuemei Tang
Patients with pediatric rheumatic diseases (PRDs) have higher morbidity and mortality associated with infectious diseases. Vaccination is an effective way to prevent infection. This study aimed to understand the vaccination status, vaccination-related attitudes, and adverse reactions in patients with PRDs in one of the largest Pediatric Rheumatic and Immune centers in China. A cross-sectional study using an online questionnaire was conducted among the caregivers of patients with PRDs admitted to the Children's Hospital of Chongqing Medical University...
May 21, 2023: Human Vaccines & Immunotherapeutics
Zhuoyu Zhang, Yunyan Zhang, Jiangtao Yu, Chen Dong, Jun Zhang, Na Liu, Chihua Qian, Lin Luan
The study evaluates the outcomes of including varicella vaccines (VarV) in the local expanded programme on immunization (EPI) on the seropositivity rates and corresponding protective effects for children aged 3-6 years in Suzhou. The study is observational. Varicella prevalence in children was assessed based on data from the China Information System for Disease Control and Prevention (CISDCP) and the Jiangsu Province Vaccination Integrated Service Management Information System (JPVISMIS). Seropositivity was determined using the enzyme-linked immunosorbent assay (ELISA)...
May 19, 2023: Human Vaccines & Immunotherapeutics
Maiya Block Ngaybe, Harrison J Schmitt, Stephanie Mallahan, Riley Sena, Samantha Werts, Brianna Rooney, Priscilla Magrath, Purnima Madhivanan
In the Spring of 2021, the COVID-19 vaccination was authorized for emergency use by the Food and Drug Administration. Healthcare workers (HCWs) are one of the most trusted sources of information for vaccination choices. However, HCWs at this time appeared to continue to have lower rates of COVID-19 vaccination uptake than expected in Arizona. The objective of this study was to examine factors that play a role in the vaccination decision-making process among Arizona HCWs. Between January and April 2021, 18 semi-structured interviews were conducted among physicians, emergency medical technicians and long-term care nurses in Pima County...
May 15, 2023: Human Vaccines & Immunotherapeutics
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.